CEBPA and acute myeloid leukemia: AML itself is no longer defined solely by morphology but by distinct subtypes with recurrent genetic abnormalities or clinical contexts (such asAML with t(8;21),AML with biallelic CEBPA mutations, or therapy-related AML), replacing the old FAB M0–M7 nomenclature.3